PhOx-430 is under clinical development by Phost’IN and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PhOx-430’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PhOx-430 overview

PhOx-430 is under development for the treatment of glioblastoma multiforme, HER2- breast cancer and triple negative breast cancer. It is administered through oral route and acts by targetting GnT-V (N-acetylglucosaminyltransferase-V).

Phost’IN overview

Phost’IN is a biopharmaceutical company that includes in discovery and development of N-glycosylation inhibitors for the treatment of cancers and other major diseases. It develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism that aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors. The company’s first candidate PhO430, which is in the preclinical last stage developing for the treatment of aggressive solid tumors, including rare cancers without satisfying curative treatment, such as Triple Negative Breast Cancers and Glioblastomas. Phost’IN is headquartered in Montpellier, France.

For a complete picture of PhOx-430’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.